Cart
sales@molnova.com
Oxyphencyclimine Hydrochloride
CAS No. 125-52-0
Oxyphencyclimine Hydrochloride( —— )
Catalog No. M17223 CAS No. 125-52-0
Oxyphencyclimine Hydrochloride is a synthetic tertiary amine and antimuscarinic agent with antispasmodic and antisecretory activities.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 31 | In Stock |
|
| 5MG | 48 | In Stock |
|
| 10MG | 85 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameOxyphencyclimine Hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionOxyphencyclimine Hydrochloride is a synthetic tertiary amine and antimuscarinic agent with antispasmodic and antisecretory activities.
-
DescriptionOxyphencyclimine Hydrochloride is a synthetic tertiary amine and antimuscarinic agent with antispasmodic and antisecretory activities.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorMuscarinic AChR
-
Research AreaNeurological Disease
-
Indication——
Chemical Information
-
CAS Number125-52-0
-
Formula Weight380.91
-
Molecular FormulaC20H29ClN2O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCOc1cc(c(cc1CNC[C@@H](c1c2ccc(=O)[nH]c2c(cc1)O)O)Cl)NC(=O)CCN1CCC(CC1)OC(=O)Nc1ccccc1c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Waelbroeck M, et al. Eur J Pharmacol. 1992 Sep 1;227(1):33-42.
molnova catalog
related products
-
SRX3177
SRX3177 is a novel and potent inhibitor of BRD4, PI3K and CDK.SRX3177 has potential anticancer activity.
-
PBRM1-BD2-IN-3
PBRM1-BD2-IN-3 (compound 12) is a potent PBRM1-BD2 inhibitor with an IC50 of 1.1 μM, used in anticancer research.
-
ZEN-3694
ZEN-3694 (ZEN 3694) is a bromo-structural domain extra-terminal inhibitor (BETi) with activity in androgen signaling inhibitor (ASI) resistance models and can be used in combination with enzalutamide to study metastatic desmoplasia-resistant prostate cancer.
